The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

Lipid nanoparticles (LNPs) are the delivery vehicles of modern medicine, carrying cancer drugs, gene therapies and vaccines ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today ...

Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, today announced significant ...

Nanocarriers will play a central role in the next wave of life-saving medicines. They enable the targeted delivery of drugs, genes, or proteins to cells within patients. With SCP-Nano, researchers can ...

Our cells and the machinery inside them are engaged in a constant dance. This dance involves some surprisingly complicated choreography within the lipid bilayers that comprise cell membranes and ...

BEIJING, Sept. 29, 2025 /PRNewswire/ -- METiS TechBio, a pioneer in AI-powered nano-delivery innovation, announced the official launch of NanoForge, the world's first end-to-end AI-driven ...

(Nanowerk News) How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side effects? Researchers at Helmholtz Munich, ...